Should I buy or sell Nuwellis stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuwellis in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NUWE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUWE, but not buy additional shares or sell existing shares. View NUWE analyst ratings or view top-rated stocks .

How have NUWE shares performed in 2024?

Nuwellis' stock was trading at $0.5809 at the beginning of 2024. Since then, NUWE shares have decreased by 55.8% and is now trading at $0.2570. View the best growth stocks for 2024 here .

When is Nuwellis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our NUWE earnings forecast .

How were Nuwellis' earnings last quarter?

Nuwellis, Inc. (NASDAQ:NUWE) released its quarterly earnings data on Tuesday, March, 5th. The company reported ($2.24) earnings per share for the quarter, missing analysts' consensus estimates of ($1.39) by $0.85. The business earned $2.55 million during the quarter. Nuwellis had a negative net margin of 227.99% and a negative trailing twelve-month return on equity of 218.79%. During the same period last year, the company earned ($5.00) EPS.

When did Nuwellis' stock split?

Nuwellis's stock reverse split on the morning of Sunday, December 11th 2022. The 1-100 reverse split was announced on Sunday, December 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, December 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Nuwellis?

Shares of NUWE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NUWE

Nuwellis (NUWE) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free NUWE Stock Alerts

$0.26

0.00 (-1.31%)

(As of 04:38 PM ET)

Compare

Today's Range: $0.24
▼
$0.28
50-Day Range: $0.26
▼
$0.70
52-Week Range: $0.24
▼
$5.73

Volume: 236,196 shs
Average Volume: 737,739 shs
Market Capitalization: $1.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Nuwellis alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Nuwellis Stock (NASDAQ:NUWE)

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama. Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

NUWE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NUWE Stock News Headlines

April 9, 2024 | finance.yahoo.com

Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health

March 28, 2024 | finance.yahoo.com

Children's Minnesota Foundation Board of Directors adds six new members

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 12, 2024 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on Nuwellis (NUWE)

March 8, 2024 | finance.yahoo.com

Nuwellis Full Year 2023 Earnings: EPS Beats Expectations

March 7, 2024 | seekingalpha.com

Nuwellis, Inc. (NUWE) Q4 2023 Earnings Call Transcript

March 7, 2024 | finance.yahoo.com

Nuwellis, Inc. (NASDAQ:NUWE) Q4 2023 Earnings Call Transcript

March 7, 2024 | globenewswire.com

Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 6, 2024 | nz.finance.yahoo.com

Nuwellis, Inc. (NUWE) stock price, news, quote & history – Yahoo Finance

March 6, 2024 | finance.yahoo.com

Q4 2023 Nuwellis Inc Earnings Call

March 5, 2024 | finance.yahoo.com

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results

March 4, 2024 | benzinga.com

Earnings Preview For Nuwellis

March 4, 2024 | msn.com

Nuwellis Q4 Earnings Preview

March 4, 2024 | markets.businessinsider.com

Nuwellis earnings: here's what to expect

February 27, 2024 | globenewswire.com

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

February 24, 2024 | morningstar.com

Nuwellis Inc NUWE

February 22, 2024 | marketwatch.com

SeaStar Medical Shares Rise 10% After FDA Humanitarian Device Exemption Approval

February 22, 2024 | benzinga.com

Nuwellis Stock (NASDAQ:NUWE), Short Interest Report

February 22, 2024 | globenewswire.com

Nuwellis' Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™

February 20, 2024 | globenewswire.com

Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 20, 2024 | finance.yahoo.com

Nuwellis, Inc. (22SA.F)

February 20, 2024 | finance.yahoo.com

Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference

February 20, 2024 | globenewswire.com

Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference

February 7, 2024 | msn.com

Nuwellis Reveals Aquadex System Success in Liver Disease

February 6, 2024 | finanznachrichten.de

Nuwellis, Inc.: New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload

February 6, 2024 | finance.yahoo.com

New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload

See More Headlines

Receive NUWE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Electromedical equipment
Sub-Industry: N/A
Current Symbol: NASDAQ:NUWE
CUSIP: N/A
CIK: 1506492
Web: www.nuwellis.com
Phone: (952) 345-4200
Fax: N/A
Employees: 59
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($13.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,210,000.00
Net Margins: -227.99%
Pretax Margin: -227.90%
Return on Equity: -218.79%
Return on Assets: -140.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.59
Quick Ratio: 1.96

Sales & Book Value

Annual Sales: $8.86 million
Price / Sales: 0.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.53 per share
Price / Book: 0.48

Miscellaneous

Outstanding Shares: 6,800,000
Free Float: 6,741,000
Market Cap: $1.75 million
Optionable: Not Optionable
Beta: 0.17

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Nestor Jaramillo Jr. (Age 67)
President, CEO & Director
Comp: $437.71k
Mr. Robert B. Scott (Age 44)
Chief Financial Officer
Comp: $252.6k
Mr. Neil P. Ayotte Esq. (Age 60)
Senior VP, General Counsel, Secretary & Chief Compliance Officer
Comp: $342.54k
Mr. John Kowalczyk
Senior Vice President of Sales & Marketing
Ms. Sandra Eayrs
Chief Human Resources Officer
Mr. Vitaliy Epshteyn (Age 46)
Sr. Vice President of Operations & Engineering
Dr. John Lynn Jefferies FACC
M.D., M.P.H., Chief Medical Officer & Member of Medical Advisory Board
Mr. Paul Wotta (Age 67)
Corporate Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NUWE Stock Analysis - Frequently Asked Questions

Should I buy or sell Nuwellis stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuwellis in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NUWE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUWE, but not buy additional shares or sell existing shares.
View NUWE analyst ratings or view top-rated stocks.
How have NUWE shares performed in 2024?: Nuwellis' stock was trading at $0.5809 at the beginning of 2024. Since then, NUWE shares have decreased by 55.8% and is now trading at $0.2570.
View the best growth stocks for 2024 here.
When is Nuwellis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our NUWE earnings forecast.
How were Nuwellis' earnings last quarter?: Nuwellis, Inc. (NASDAQ:NUWE) released its quarterly earnings data on Tuesday, March, 5th. The company reported ($2.24) earnings per share for the quarter, missing analysts' consensus estimates of ($1.39) by $0.85. The business earned $2.55 million during the quarter. Nuwellis had a negative net margin of 227.99% and a negative trailing twelve-month return on equity of 218.79%. During the same period last year, the company earned ($5.00) EPS.

When did Nuwellis' stock split?: Nuwellis's stock reverse split on the morning of Sunday, December 11th 2022. The 1-100 reverse split was announced on Sunday, December 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, December 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.
How do I buy shares of Nuwellis?: Shares of NUWE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NUWE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nuwellis (NUWE) Stock Price, News & Analysis

About Nuwellis Stock (NASDAQ:NUWE)

NUWE Stock Price History

NUWE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

NUWE Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info